Vivalyx is a technology company.
Vivalyx has raised $2.0M across 1 funding round.
Vivalyx has raised $2.0M in total across 1 funding round.
Vivalyx has raised $2.0M in total across 1 funding round.
Vivalyx's investors include 20VC, Accel, Mantis VC, TQ Ventures, Kevin Weil, Lior Shiff, Riccardo Zacconi, Ron Pragides, Scott Belsky.
Vivalyx is a medtech startup founded in 2022 that develops Omnisol, a patented, fully synthetic blood substitute for organ preservation and revitalization during transplantation.[1][2][3][4] It serves transplant centers, hospitals, and patients on organ waiting lists by addressing the global shortage of viable donor organs—currently meeting less than 20% of needs—through body-temperature perfusion that enhances organ vitality without donor blood, outperforming blood-based methods by 3x in preclinical trials and potentially expanding the organ pool 3-4x.[2][4][6] The company has raised over $5.7M in funding, including a €2.5M grant and up to €6M equity commitment from the European Innovation Council (EIC) Accelerator in 2025, with 14 employees and investors like TechVision Fund and Nextgen Ventures.[1][2][5]
This innovation tackles scalability issues in warm perfusion, making it affordable and reproducible for clinical use, with applications in transplants, autotransplantation for cancer treatments, and beyond.[2][4]
Vivalyx GmbH was founded in 2022 in Aachen, Germany, by a team of experts: Dr. Andreas Schumacher, Dr. Benedict Doorschodt, Prof. Dr. René Tolba, PD Dr. Christian Bleilevens, Prof. Dr. Malte Brettel, and Marius Rosenberg, combining backgrounds in medicine, medical technology, regulatory affairs, and entrepreneurship.[2][3] Emerging from RWTH Aachen University, the idea stemmed from the limitations of current organ preservation—reliance on scarce donor blood for warm perfusion, which hinders scalability despite its superiority for assessing and revitalizing marginal organs.[4][6] Early traction came from preclinical trials showing Omnisol's superior performance, attracting initial funding like $5.79M from TechVision Fund, and culminating in the major EIC Accelerator award in February 2025 to push toward regulatory approval.[1][2]
Vivalyx rides the organ transplant crisis trend, where demand far outstrips supply amid aging populations and rising organ failure cases in Europe and globally.[4] Timing aligns with advances in machine perfusion and regulatory support via EU programs like EIC, addressing warm perfusion's untapped potential blocked by blood scarcity.[2][4] Market forces favoring synthetic biologics, cost pressures on healthcare, and scalability demands in medtech propel it; as a RWTH Aachen spin-off, it influences the ecosystem by pioneering blood-independent solutions, potentially standardizing preservation and boosting transplant rates while inspiring similar innovations in regenerative medicine.[3][6]
Vivalyx is poised for regulatory approval of Omnisol within two years via its EIC project, expanding team and clinical trials to capture the transplant market.[2] Trends like AI-optimized perfusion, personalized medicine, and EU medtech funding will shape its path, evolving its influence from niche revitalization to mainstream organ therapy platforms. With preclinical dominance and strategic backing, it could transform transplant accessibility, directly tying back to its mission of saving lives through more viable organs.
Vivalyx has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $2.0M Seed | 20VC, Accel, Mantis VC, TQ Ventures, Kevin Weil, Lior Shiff, Riccardo Zacconi, Ron Pragides, Scott Belsky |